Abstract
Anlotinib is an oral multi-target tyrosine kinase inhibitor, mainly targets VEGFR1-3, FGFR 1-4, PDGFR α/β and c-kit. Previous trial has demonstrated that anlotinib monotherapy was effective and safe in advanced colorectal cancer following the failure of standard treatment. ALTER-C002 trial was designed to evaluate the efficacy and safety of anlotinib plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer (mCRC). Preliminary results demonstrated significant antitumor activity and manageable toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
